Jakavi is a medicine used to treat the following conditions: - splenomegaly (enlarged spleen) or other disease-related symptoms such as fever, night sweats, bone pain and weight loss in adults who have myelofibrosis. Myelofibrosis is a disease in which the bone marrow becomes very dense and rigid and produces abnormal, immature blood cells; - polycythaemia vera in adults in whom the medicine hydroxycarbamide (also known as hydroxyurea) does not work or causes unacceptable side effects. In polycythaemia vera, too many red blood cells are produced, which can cause reduced blood flow to the organs due to ‘thickening’ of the blood and occasionally the formation of blood clots; - acute graft-versus-host disease (GvHD, when donor cells attack the body shortly after a transplant) in adults and children aged 28 days and older for whom corticosteroids or other systemic therapies (treatments given by mouth or injection) did not work well enough; - chronic graft-versus-host-disease (which usually develops later than acute GvHD, within several weeks to months after a transplant) in adults and children aged 6 months and older for whom corticosteroids or other systemic therapies did not work well enough. Jakavi contains the active substance ruxolitinib.
Therapeutic Indication
### Therapeutic indication **Myelofibrosis (MF)** Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. **Polycythaemia vera (PV)** Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. **Graft versus host disease (GvHD)** **Acute GvHD** Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). **Chronic GvHD** Jakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). **Myelofibrosis (MF)** Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. **Polycythaemia vera (PV)** Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. **Graft versus host disease (GvHD)** **Acute GvHD** Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). **Chronic GvHD** Jakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
L01EJ01
ATC Item
ruxolitinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ruxolitinib phosphate | N/A | 磷酸芦可替尼 |
EMA Name
Jakavi
Medicine Name
Jakavi
Aliases
N/ANo risk management plan link.
